KINIKSA PHARMACEUTICALS LTD

NASDAQ: KNSA (Kiniksa Pharmaceuticals Interna)

Last update: 2 hours ago

96.33

0.05 (0.05%)

Previous Close 96.28
Volume 465,632
Price / Earnings (Forward) 60.64
Price / Sales 8.48
Price / Book 10.66
52 Weeks Range
37.02 (-61%) — 99.31 (3%)
Profit Margin -3.52%
Operating Margin (TTM) 9.63%
Diluted EPS (TTM) -0.240
Quarterly Revenue Growth (YOY) 72.50%
Total Debt/Equity (MRQ) 2.17%
Current Ratio (MRQ) 3.66
Operating Cash Flow (TTM) 44.03 M
Levered Free Cash Flow (TTM) 25.15 M
Return on Assets (TTM) -1.77%
Return on Equity (TTM) -3.81%

AIStockmoo Score

1.5
Value 30% 0.0
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Low debt. Weak profitability. Ample short-term liquidity. Positive cash flow. info
Return on Capital info NA
Timing 30% 3.3
From our AI technical analysis of the chart. info NA
Uptrend over the past year. Trading near its 52-week high. info
Recent bearish reversal pattern: Hanging man. info
Trend for Your Holding Period info NA
Sentiment 20% 0.0
No recent price targets, so based on how targets have been revised. info
News Mood info NA
Smart Money 20% 1.6
No clear net insider buying or selling. info
Institutions net +7.26% of shares in their latest 13F filings: 198 holders increased, 110 decreased (quarter to 30 Sep 2026). info
Short interest +13.4% from 31 Aug to 30 Oct 2026, 3.9 days to cover (FINRA). info
Market and sector conditions are poor.
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Not in score
Price is high against its 52-week average. Up over 5 years. info
Trend up on all three terms. Short-term momentum rising. info
Price is between support and resistance. Levels trending up. info
Final Score 1.54

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Mixed Mixed
Drug Manufacturers - Specialty & Generic (Global) Mixed Mixed
Stock Kiniksa Pharmaceuticals Interna Mixed Bearish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
KNSA - - - 10.66
ALVO - - - -
BCRX - - - -
LQDA - - - 21.86
RDHL - - - 0.570
GELS - - - 0.430

Select this tab to load the latest available analysis.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Small Growth
% Held by Insiders 3.80%
% Held by Institutions 97.31%

Ownership

Name Date Shares Held
Rubric Capital Management Lp 30 Jun 2026 3,999,800
Baker Bros. Advisors Lp 30 Jun 2026 2,834,643
Tang Capital Management Llc 30 Jun 2026 2,259,889
Spruce Street Capital Lp 30 Sep 2026 918,070
Pictet Asset Management Holding Sa 30 Sep 2026 860,228
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
MEGNA MICHAEL R - 98.76 -11,280 -1,114,013
MOAT ROSS - 90.80 -27,977 -2,540,312
PAOLINI JOHN F. - 90.80 -18,413 -1,671,900
PATEL SANJ K - 93.74 -460,903 -43,203,132
RAGOSA MARK - 90.80 -36,783 -3,339,896
Aggregate Net Quantity -555,356
Aggregate Net Value ($) -51,869,253
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 93.40
Name Holder Date Type Quantity Price Value ($)
MEGNA MICHAEL R Officer 09 Nov 2026 Automatic sell (-) 11,280 98.76 1,114,013
MEGNA MICHAEL R Officer 09 Nov 2026 Option execute 11,280 - -
PATEL SANJ K Officer 04 Nov 2026 Automatic sell (-) 151,300 96.12 14,542,956
PATEL SANJ K Officer 04 Nov 2026 Option execute 145,763 - -
PATEL SANJ K Officer 03 Nov 2026 Automatic sell (-) 220,170 93.29 20,539,659
PATEL SANJ K Officer 03 Nov 2026 Option execute 130,326 - -
MOAT ROSS Officer 02 Nov 2026 Automatic sell (-) 27,977 90.80 2,540,312
MOAT ROSS Officer 02 Nov 2026 Option execute 27,977 - -
PAOLINI JOHN F. Officer 02 Nov 2026 Automatic sell (-) 18,413 90.80 1,671,900
PAOLINI JOHN F. Officer 02 Nov 2026 Option execute 18,413 - -
RAGOSA MARK Officer 02 Nov 2026 Automatic sell (-) 36,783 90.80 3,339,896
RAGOSA MARK Officer 02 Nov 2026 Option execute 36,783 - -
PATEL SANJ K Officer 02 Nov 2026 Automatic sell (-) 89,433 90.80 8,120,516
PATEL SANJ K Officer 02 Nov 2026 Option execute 53,381 - -
Show more

Institutions

Institutional ownership: 109.38%

Positions Holders Shares
Increased 198 7,140,706
Decreased 110 5,523,188
New 81 2,633,937
Sold out 26 693,278

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 4,294,644 3.9
15 Oct 2026 3,763,527 6.8
30 Sep 2026 3,778,657 6.4
15 Sep 2026 3,876,769 7.2
31 Aug 2026 3,788,699 8.7
14 Aug 2026 4,283,628 9.6

FINRA short interest via Nasdaq, reported twice a month.

0 Positive 0 Negative 1 Neutral
Date Type Details
11 Nov 2026 Yahoo Finance Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
LONDON, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 11:00 a.m. Greenwich Mean Time (6:00 a.m.…
30 Oct 2026 Yahoo Finance Stock Market: Google, Amazon, Intel, ServiceNow Trigger Tech Wreck, But Other Sectors Solid: Weekly Review
The stock market saw the major indexes ultimately fall for the week as Google, Amazon, Intel and ServiceNow led a tech wreck. But many sectors thrived.
28 Oct 2026 Yahoo Finance Kiniksa (KNSA) Stock Jumps As Q3 Results Fuel Growth Debate
Kiniksa Pharmaceuticals stock exploded 22.2% higher to US$89.20 on Wednesday after traders digested fresh Q3 2026 results. The move caps a strong recent run, yet the real story sits in the earnings print itself. ARCALYST revenue hit US$286 million for the quarter and net income reached US$47.3…
27 Oct 2026 Yahoo Finance Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
Profit growth is outpacing revenue gains, giving the company firepower to advance pipeline candidates without diluting shareholders.
27 Oct 2026 Yahoo Finance Kiniksa Pharmaceuticals, Ltd. Q3 2026 Earnings Call Summary
Moby summary of Kiniksa Pharmaceuticals, Ltd.'s Q3 2026 earnings call…
27 Oct 2026 Yahoo Finance Kiniksa (KNSA) Q3 2026 Earnings Call Transcript
ARCALYST revenue surged 58% year-over-year as the company raised full-year guidance.
27 Oct 2026 Yahoo Finance What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) raised its full-year 2026 revenue guidance after reporting third-quarter ARCALYST revenue growth of 58% year over year, as the company continued to expand use of the drug for recurrent pericarditis and advance its clinical pipeline. The company no…
27 Oct 2026 Yahoo Finance Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of +75.00% and +10.19%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
27 Oct 2026 Yahoo Finance Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion –– KPL-387 pivotal Phase 3 data expected in 2H 2027 –– Conference call and webcast scheduled for 8:30 am…
24 Oct 2026 Yahoo Finance 3 Healthcare Stocks To Watch In October 2026
Americans now have a record share of their financial assets in equities, which raises the stakes for choosing where every new dollar goes. With so much capital already tied to markets, investors are paying closer attention to sectors that can offer essential services through different economic…
22 Oct 2026 Yahoo Finance Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern Time to report its third quarter 2026 financial results and recent portfolio…
17 Oct 2026 Yahoo Finance GeneDx Holdings And 2 Other Top Healthcare Stocks
High interest costs are squeezing governments and households, yet healthcare remains a non‑discretionary spend that people rarely cut. That combination keeps attention on financially solid medical businesses with resilient demand for treatments, equipment and services. The opportunity is clear for…
14 Oct 2026 Yahoo Finance Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight
Boosted by its exclusive agreement with Regeneron, Kiniksa Pharmaceuticals stands among the top biotech stocks to watch.
23 Sep 2026 Yahoo Finance Kiniksa Pharmaceuticals International (KNSA) On The ARCALYST Story And Whether Shares Look Fully Valued
Kiniksa Pharmaceuticals International (KNSA) has drawn fresh attention after recent share performance data highlighted sharp swings, with the stock down about 4% over the past month but up roughly 34% in the past 3 months. Short term momentum for Kiniksa Pharmaceuticals International has cooled a…
17 Sep 2026 Yahoo Finance Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.
10 Sep 2026 Yahoo Finance Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat
Biotech leader Kiniksa stock is poised to hit a fresh buy point after shares soared 25% in response to better-than-expected sales numbers.
04 Sep 2026 Yahoo Finance Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time. A live webcast of…
24 Aug 2026 Yahoo Finance TGTX Stock Outperforms 95% of Stocks. Here's Why.
Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average.
21 Aug 2026 Yahoo Finance Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan
Sales of Kiniksa Pharmaceuticals' biggest product, Arcalyst, are expected to begin declining in 2030. But the company has a plan.
Show more

Recent Signals candle patterns and EMA crosses

▼ Hanging man Last session · 13 Nov
A long lower shadow after a rise: sellers are showing up. Needs a lower close next to confirm.

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria